Page last updated: 2024-12-09

oxazolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxazolone: Immunologic adjuvant and sensitizing agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1712094
CHEMBL ID3188911
SCHEMBL ID248341
MeSH IDM0015642

Synonyms (42)

Synonym
oxazolone (sensitizing agent)
2-oxazolin-5-one, 4-ethoxymethylene-2-phenyl-
4-ethoxymethylene-2-phenyl-2-oxazolin-5-one
einecs 239-713-9
4-ethoxymethylene-2-phenyl-2-oxazoline-5-one
oxazolone
5(4h)-oxazolone, 4-(ethoxymethylene)-2-phenyl-
15646-46-5
4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, technical grade
4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, purified by recrystallization
AKOS000267145
HMS1727F01
(4z)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one
(4z)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5(4h)-one
STL133422
3clc92z7wp ,
unii-3clc92z7wp
tox21_202808
cas-15646-46-5
dtxcid7029081
dtxsid1049225 ,
NCGC00260354-01
5(4h)-oxazolone,4-(ethoxymethylene)-2-phenyl-
SCHEMBL248341
(z)-4-(ethoxymethylene)-2-phenyloxazol-5(4h)-one
2-oxazolin-5-one, 4-(ethoxymethylene)-2-phenyl-
4-ethoxymethylene-2-phenyloxazol-5-one
4-ethoxymethylene-2-phenyl oxazolone
4-ethoxymethylene-2-phenyloxazolin-5-one
2-phenyl-4-(ethoxymethylene)oxazolone
4-(ethoxymethylene)-2-phenyl-1,3-oxazol-5(4h)-one #
CHEMBL3188911
4-ethoxymethylene-2-phenyl-5-oxazolone, (4z)-
78IL0J7N72 ,
60777-96-0
5(4h)-oxazolone, 4-(ethoxymethylene)-2-phenyl-, (4z)-
5(4h)-oxazolone, 4-(ethoxymethylene)-2-phenyl-, (z)-
unii-78il0j7n72
mfcd00003204
4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, analytical standard, for drug analysis
Q27266670
(4z)-4-ethoxymethylene-2-phenyl-5-oxazolone

Research Excerpts

Overview

Oxazolone (OXA) is a potent contact allergen in man. It is used as a model Th1-allergen to test (Q)SAR's and screening assays for allergenic potential of chemicals.

ExcerptReferenceRelevance
"Oxazolone is a well-characterised contact allergen."( FcRγ promotes contact hypersensitivity to oxazolone without affecting the contact sensitisation process in B6 mice.
Nunomura, S; Ohtsubo-Yoshioka, M; Okayama, Y; Ra, C; Terui, T, 2015
)
1.4
"Oxazolone (OXA) is a potent contact allergen in man, and it is used as a model Th1-allergen to test (Q)SAR's and screening assays for allergenic potential of chemicals. "( Oxazolone (OXA) is a respiratory allergen in Brown Norway rats.
Arts, JH; de Groot, RJ; Kuper, CF; Radonjic, M; Stierum, R; van Triel, J, 2011
)
3.25
"The oxazolone scaffold is a novel cysteine peptidase inhibitor; it may thus find widespread use."( Identification of lead compounds targeting the cathepsin B-like enzyme of Eimeria tenella.
Coombs, GH; Gassel, M; Heckeroth, AR; Mottram, JC; Noack, S; Schaeffer, M; Schroeder, J; Selzer, PM, 2012
)
0.86
"Oxazolone colitis (OC) is an experimental colitis that has a histologic resemblance to human ulcerative colitis. "( Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells.
Blumberg, RS; Fuss, IJ; Heller, F; Nieuwenhuis, EE; Strober, W, 2002
)
3.2
"Oxazolone colitis is a T helper cell type 2 (Th2)-mediated process since stimulated T cells from lesional tissue produce markedly increased amounts of interleukin (IL)-4 and IL-5; in addition, anti-IL-4 administration leads to a striking amelioration of disease, whereas anti-IL-12 administration either has no effect or exacerbates disease."( Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4.
Boirivant, M; Chu, A; Fuss, IJ; Strober, W, 1998
)
2.46

Effects

ExcerptReferenceRelevance
"Oxazolone has been demonstrated to induce significant skin inflammation and produce inflammatory cytokine expression identical to that of AD."( Dictamnine delivered by PLGA nanocarriers ameliorated inflammation in an oxazolone-induced dermatitis mouse model.
Chan, LY; Chang, TM; Hsieh, YT; Huang, HC; Lin, CY; Maeda, T; Yang, TY, 2021
)
1.57

Treatment

Oxazolone treatment stimulated maturation of pro-caspase-1 and pro-IL-1β, while it reduced IL-18 expression. Treatment with oxazol one resulted in ulcerations particularly at CP with follicular expansion as well as colitis.

ExcerptReferenceRelevance
"Oxazolone treated rats were divided into untreated oxazolone group, metformin and mesalazine treated groups both in a dose of 100 mg/kg/day orally for 21 days."( Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: plausible role of sphingosine kinase 1/sphingosine 1 phosphate signaling pathway.
Abu-Risha, SE; El-Kadem, AH; El-Mahdy, NA; El-Sayad, ME, 2021
)
1.62
"Oxazolone treatment stimulated maturation of pro-caspase-1 and pro-IL-1β, while it reduced IL-18 expression."( NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis.
Arakawa, T; Fujiwara, Y; Hosomi, S; Itani, S; Kamata, N; Nadatani, Y; Nagami, Y; Otani, K; Shiba, M; Shimada, S; Sugimura, N; Takeda, S; Tanaka, F; Tanigawa, T; Tominaga, K; Watanabe, T; Yamagami, H, 2016
)
1.41
"Treatment with oxazolone resulted in ulcerations particularly at CP with follicular expansion as well as colitis."( B cell activation in the cecal patches during the development of an experimental colitis model.
Adachi, T; Hosoya, A; Jose, N; Karasuyama, H; Kojima, Y; Nagaishi, T; Nakamura, T; Nemoto, Y; Onizawa, M; Oshima, S; Tsugawa, N; Watabe, T; Watanabe, M, 2018
)
0.82

Bioavailability

ExcerptReferenceRelevance
" Sodium cromoglycate and nedocromil sodium, which are poorly absorbed from the gastrointestinal tract, were tested by intraperitoneal administration."( LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity.
Bonhomme, Y; Brown, T; Murray, N; Zoerkler, N, 1994
)
0.54
" In addition, theoretical studies have shown that PB3 is characterized by good bioavailability and absorption/transmission across the cell membrane."( Synthesis, photophysical and biological properties of a new oxazolone fluorescent probe for bioimaging: an experimental and theoretical study.
Cysewski, P; Janek, T; Jędrzejewska, B; Krawczyk, P, 2017
)
0.7
" To increase the bioavailability and GluN2B affinity, the phenol of the potent benzazepine-based inhibitor, WMS-1410 (3), was replaced bioisosterically by a benzoxazolone moiety and the phenylbutyl side chain was conformationally restricted in a phenylcyclohexyl substituent."( Phenol-benzoxazolone bioisosteres of GluN2B-NMDA receptor antagonists: Unexpected rearrangement during reductive alkylation with phenylcyclohexanone.
Daniliuc, C; Frehland, B; Fröhlich, R; Goerges, G; Markus, A; Schepmann, D; Schreiber, JA; Seebohm, G; Wünsch, B, 2022
)
1.31

Dosage Studied

c(ILDV-NH(CH2)5CO) inhibited ovalbumin delayed-type hypersensitivity or oxazolone contact hypersensitivity in Balb/c mice.

ExcerptRelevanceReference
" It was found that the lack of a continuous high blast cell activity in the paracortex was a physiological response that could be observed with high dosage as well as with very low dosage."( Dose dependency of the responses in draining lymph nodes and skin to repeated applications of oxazolone. A quantitative and histological study in mice.
Myking, AO, 1979
)
0.48
" In dose-response studies, a 50% reduction in ear swelling was achieved with as little as 20 micrograms of pentamidine."( Pentamidine isethionate reduces Ia expression and antigen presentation by Langerhans cells and inhibits the contact hypersensitivity reaction.
Blaylock, BL; Comment, CE; Corsini, E; Kouchi, Y; Luster, MI; Rosenthal, GJ, 1991
)
0.28
" Dose-response studies showed a 44% reduction in ear swelling with 30 ng of T-2 toxin as compared with a similar reduction with 300 ng of dexamethasone."( Topical application of T-2 toxin inhibits the contact hypersensitivity response in BALB/c mice.
Blaylock, BL; Comment, CE; Kouchi, Y; Luster, MI; Pollock, PL, 1993
)
0.29
" A dose-response study showed that the lowest concentration of chlordane resulting in a significantly reduced ear swelling response was 20 micrograms per ear."( Topical exposure to chlordane reduces the contact hypersensitivity response to oxazolone in BALB/c mice.
Bartow, TA; Blaylock, BL; Holladay, SD; Mehendale, HM; Newsom, KK; Shipp, BK, 1995
)
0.52
" Dose-response studies with standard contact and photocontact allergens as well as irritants and photoirritants revealed that irritants predominantly induced skin inflammation, which in turn stimulated draining lymph node cell proliferation."( An integrated model for the differentiation of chemical-induced allergic and irritant skin reactions.
Ahr, HJ; Blümel, J; Homey, B; Lehmann, P; Ruzicka, T; Schuppe, HC; Vohr, HW; von Schilling, C, 1998
)
0.3
" c(ILDV-NH(CH2)5CO) inhibited ovalbumin delayed-type hypersensitivity or oxazolone contact hypersensitivity in Balb/c mice when dosed continuously from subcutaneous osmotic mini-pumps (0."( Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion.
Alcock, PJ; Dutta, AS; Gormley, JJ; Haworth, D; Jamieson, A; Jones, HB; Rees, A; Reilly, CF; Wood, LJ, 1999
)
0.54
" The sensitizing capacity of known allergens was quantified by dose-response modeling."( A quantitative method for assessing the sensitizing potency of low molecular weight chemicals using a local lymph node assay: employment of a regression method that includes determination of the uncertainty margins.
de Jong, WH; Slob, W; van Loveren, H; van Och, FM; Vandebriel, RJ, 2000
)
0.31
" Dose-response studies showed that a majority of mice (68%) treated with rCT-B at a dose of 100 microg (times four daily doses) exhibited complete inhibition of the development of colitis, whereas a minority (30%) treated with rCT-B at a dose of 10 microg (times four daily doses) exhibited complete inhibition; in both cases, however, the remaining mice exhibited some reduction in the severity of inflammation."( Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis.
Boirivant, M; De Pascale, M; Ferroni, L; Fuss, IJ; Strober, W, 2001
)
0.31
" Allergen-induced changes in these three genes were confirmed in dose-response and kinetic analyses using Northern blotting and/or reverse transcription-polymerase chain reaction techniques."( Assessment of glycosylation-dependent cell adhesion molecule 1 as a correlate of allergen-stimulated lymph node activation.
Betts, CJ; Caddick, HT; Cumberbatch, M; Dearman, RJ; Frank Gerberick, G; Hulette, BC; Kimber, I; Moggs, JG; Orphanides, G; Ryan, CA, 2003
)
0.32
" Quantitative analyses showed that the dose-response relationship for each chemical followed a cubic trend."( Acute stress modulates the irritant component of sensitizers in allergic contact dermatitis: implications for exposure assessment.
Brumbaugh, K; Flint, MS; Salmen, RR; Tinkle, SS, 2003
)
0.32
" The complexity of these dose-response relationships is likely due to the dual role of peroxynitrite as both an oxidant and a nucleophile in competition with water."( Quantitation of four guanine oxidation products from reaction of DNA with varying doses of peroxynitrite.
Tannenbaum, SR; Venkatarangan, L; Wishnok, JS; Yu, H, 2005
)
0.33
" The assay involves dosing mice with the chemical on both ears and pooling the superficial parotid lymph nodes for assessment of lymphocyte proliferation as a marker of sensitization."( Increased cell proliferation in spleen and lymph nodes peripheral to contact allergen application site.
Anderson, SE; Beezhold, D; Butterworth, LF; Chipinda, I; Siegel, PD, 2009
)
0.35
" The pigs were sensitized with oxazolone, re-challenged with the same irritant six days later, and dosed with either vehicle or with cyclosporine A (CsA) before and after challenge."( Oxazolone-induced delayed type hypersensitivity reaction in the adult yucatan pigs. A useful model for drug development and validation.
Damaj, BB; Maghazachi, AA; Nuhaily, S, 2009
)
2.08
" Mice were challenged on day 21 by topical application on the ears in a dose-dependent manner and dose-response data were used to calculate the elicitation potency."( A quantitative approach to assess the potency of skin sensitizers in the elicitation phase.
de Jong, WH; de Klerk, A; Ezendam, J; van Loveren, H; Vermeulen, JP, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency57.57160.006038.004119,952.5996AID1159521; AID1159523
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency52.53420.001022.650876.6163AID1224838; AID1224839; AID1224893
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency42.86500.001530.607315,848.9004AID1224841; AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.74610.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency64.48950.000723.06741,258.9301AID743122
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.001419.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency46.06310.057821.109761.2679AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.31070.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,123)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990272 (24.22)18.7374
1990's218 (19.41)18.2507
2000's272 (24.22)29.6817
2010's296 (26.36)24.3611
2020's65 (5.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.29 (24.57)
Research Supply Index7.05 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.09%)5.53%
Reviews22 (1.92%)6.00%
Case Studies2 (0.17%)4.05%
Observational0 (0.00%)0.25%
Other1,123 (97.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]